Are you Dr. Elkashef?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 26 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2139 Tysons Executive Ct
Dunn Loring, VA 22027Phone+1 703-849-8497
Summary
- Dr. Ahmed Elkashef, MD is a board certified psychiatrist in Dunn Loring, Virginia. He is currently licensed to practice medicine in Virginia.
Education & Training
University of Maryland/Sheppard PrattResidency, Psychiatry, 1988 - 1990
Prisma Health/University of South Carolina SOM Columbia (Columbia)Residency, Psychiatry, 1986 - 1987
Cairo University School of MedicineClass of 1977
Certifications & Licensure
VA State Medical License 1990 - 2020- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 Start of enrollment: 2001 Mar 01
- Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence Start of enrollment: 2007 Dec 01
- Vigabatrin Ph 1 Cocaine Interaction Study Start of enrollment: 2008 Feb 01
Publications & Presentations
PubMed
- 21 citationsA comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline.Thomas F. Newton, Richard De La Garza, Timothy W. Fong, Nora Chiang, Tyson H. Holmes
Pharmacology, Biochemistry, and Behavior. 2005-12-01 - 70 citationsVitamin E in the treatment of tardive dyskinesia.Ahmed Elkashef, Ruskin Pe, Bacher N, Barrett D
The American Journal of Psychiatry. 1990-01-04 - 105 citationsTreatment of tardive dyskinesia with vitamin E.Michael F. Egan, Thomas M. Hyde, Gregory W. Albers, Ahmed Elkashef, R C Alexander
The American Journal of Psychiatry. 1992-06-01
Press Mentions
Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in ImmunocompetenceMay 7th, 2020
INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of NaloxoneDecember 18th, 2018
INSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations Versus Intramuscular and Intravenous Naloxone for Opioid OverdoseNovember 1st, 2018
